Tag Archives: NASDAQ:SRPT

Sanofi’s (NYSE:SNY) Genzyme Division Gets Approval for Thyrogen – SNY, MRK, PFE, GALE, ACRX, JNJ, ACHC, SRPT, ABT

Posted on December 7, 2012 by Thomas Vedder

Sanofi’s(NYSE:SNY) Genzyme division has got European Commission authorization of a product label development for the use of Thyrogen, its cure for thyroid cancer.

Thyrogen is used to cure patients with well-distinguished thyroid cancer. The drug is accepted as an adjunctive …

Posted in Healthcare, Latest Headlines | Tagged Abbott Laboratories, ABT, Acadia Healthcare, AcelRx Pharmaceuticals, ACHC, ACRX, GALE, Galena Biopharma, JNJ, Johnson, Merck, MRK, NASDAQ:ACHC, NASDAQ:ACRX, NASDAQ:GALE, NASDAQ:SRPT, NYSE:ABT, NYSE:JNJ, NYSE:MRK, NYSE:PFE, NYSE:SNY, PFE, Pfizer, Sanofi, Sarepta Therapeutics, SNY, SRPT | Comments Off

Bernstein Research Analysts Shatters Boston Scientific (NYSE:BSX) Stock Rating to Market Perform – BSX, JNJ, ABT, ACAD, PFE, MYL, MRK, BMY, SRPT

Posted on November 27, 2012 by Thomas Vedder

Boston Scientific Corporation (NYSE:BSX) stock rating was shattered by Bernstein Research analysts on Tuesday to market-perform from their prior rating of outperform.

Analyst of the Bernstein Research kept their price target on the company stock at $6 per share.

Analyst …

Posted in Healthcare, Latest Headlines | Tagged Abbott Laboratories, ABT, ACAD, ACADIA Pharmaceuticals, BMY, Boston Scientific, Bristol-Myers Squibb, BSX, JNJ, Johnson & Johnson, Merck, MRK, MYL, Mylan, NASDAQ:ACAD, NASDAQ:MYL, NASDAQ:SRPT, NYSE:ABT, NYSE:BMY, NYSE:BSX, NYSE:JNJ, NYSE:MRK, NYSE:PFE, PFE, Pfizer, Sarepta Therapeutics, SRPT | Comments Off

UnitedHealth (NYSE:UNH) 2013 Profit Forecasts Misses Wall Street Estimates – UNH, AET, HUM, BSX, SRPT, CTIC, PFE, ARNA, JNJ

Posted on November 26, 2012 by Geoff Noir

UnitedHealth Group Inc (NYSE:UNH), the biggest United States private health insurer, reported on Monday that it projected earnings in the range of $5.25 to $5.50 a share in 2013, lower than analysts’ forecasts.

The company reported that revenue should be …

Posted in Healthcare, Latest Headlines | Tagged AET, Aetna, Arena Pharmaceuticals, ARNA, Boston Scientific, BSX, Cell Therapeutics, CTIC, HUM, Humana, JNJ, Johnson & Johnson, NASDAQ:ARNA, NASDAQ:CTIC, NASDAQ:SRPT, NYSE:AET, NYSE:BSX, NYSE:HUM, NYSE:JNJ, NYSE:PFE, NYSE:UNH, PFE, Pfizer, Sarepta Therapeutics, SRPT, UNH, UnitedHealth | Comments Off

GlaxoSmithKline (NYSE:GSK) Plans to Buy Additional Stock in Indian Unit – GSK, MRK, NVS, SRPT, CTIC, SQNM, ESRX, STJ, GILD

Posted on November 26, 2012 by Thomas Vedder

GlaxoSmithKline PLC (NYSE:GSK)has shown interest in purchasing a further stake of almost 31.8% in its Indian division, GlaxoSmithKline Consumer Healthcare Ltd. , at 3,900 rupees ($70.3) a share, the UK-located firm stated in a report on Monday.

The proposal is …

Posted in Healthcare, Latest Headlines | Tagged Cell Therapeutics, CTIC, ESRX, Express Scripts, GILD, Gilead Sciences, GlaxoSmithKline, GSK, Jude Medical, Merck, MRK, NASDAQ:CTIC, NASDAQ:ESRX, NASDAQ:GILD, NASDAQ:SQNM, NASDAQ:SRPT, Novartis, NVS, NYSE:GSK, NYSE:MRK, NYSE:NVS, NYSE:STJ, Sarepta Therapeutics, Sequenom, SQNM, SRPT, STJ | Comments Off

Quick Snapshot of Healthcare Sector; NuVasive (NUVA) Disappoints Investors with Q3 Revenue Forecast while CollabRx (CLRX) Inks Deal with Life Technologies (LIFE) – NUVA, LIFE, PFE, SRPT, BIOL, RIGL

Posted on October 4, 2012 by Geoff Noir

Healthcare sector responded positively on Wednesday’s trading session and sector surged +0.39%. If we look at the top movers of the sector so Sarepta Therapeutics Inc. (NASDAQ:SRPT) and BIOLASE Inc. (NASDAQ:BIOL) were major percentage gainers while major percentage Loser was …

Posted in Healthcare, Latest Headlines | Tagged BIOL, BIOLASE, LIFE, NASDAQ:BIOL, NASDAQ:LIFE, NASDAQ:NUVA, NASDAQ:RIGL, NASDAQ:SRPT, NUVA, NuVasive, NYSE:PFE, PFE, Pfizer, Rigel, RIGL, Sarepta Therapeutics, SRPT | Comments Off

Stock Market Quotes and Streaming Charts - QuoteDaddy.com Level 2 Stock Quotes from Quote Daddy on Vimeo.

blogs

Lorimer Wilson Analyst

Dian L. Chu "EconMatters"

Paul Ebeling Trading News

Warren Bevan Precious Metals

eStocksDaily.com ("ESD") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities customers should buy or sell for themselves. The employees or affiliates of ESD may hold positions in the stocks or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities. ESD, the authors, the publisher, and all affiliates of ESD assume no responsibility or liability for your trading and investment results. Factual statements on the ESD's website, or in its publications, are made as of the date stated and are subject to change without notice. For ESD full disclaimer and disclosure go to our disclaimer page.It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by ESD are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of ESD's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on ESD's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.